"studyInvestigationalInterventions","uuid:ID","id","bcCategories","studyDesignRationale","description","label","studyEstimands","documentVersion","name"
"[]","2e749719-74c5-47c7-90d3-f6de8e12b11d","StudyDesign_1","[]","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","","[]","","Study Design 1"
